Olive (Olea europaea) leaf extract effect on glucose and inflammation

Olive (Olea europaea) leaf extract effect on glucose metabolism and liver function and biomarkers of inflammation in patients with high blood presurer

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20170430033730N5

Enrollment

Registered

2018-09-25

Start date

2017-10-23

Completion date

Unknown

Last updated

2018-10-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Essential hypertension. Essential (primary) hypertension

Interventions

Intervention 1: Intervention group: Two capsules of 275 mg of extract were taken twice daily for twelve weeks. Intervention 2: Control group: Two capsules of 250 mg of placebo were taken twice a day

Eligibility

Sex/Gender

All

Age

30 Years to 70 Years

Inclusion criteria

Inclusion criteria: Systolic blood pressure (SBP) above 140 mmHg Diastolic blood pressure (DBP) above 90 mmHg.

Exclusion criteria

Exclusion criteria: Patients who do not want to cooperate; Hypertensive patients who have others complications such as: kidney disease? neuropathy and retinopathy; Patients with hypo and/or hyperthyroidism are excluded from this study.

Design outcomes

Primary

Measure	Time frame
FBS. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: Spectrophotometry.;Insulin. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: ELISA.	—

Secondary

Measure	Time frame
AST. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: Spectrophotometry.;ALT. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: Spectrophotometry.;ALKP. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: Spectrophotometry.;TP. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: Spectrophotometry.;Alb. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: Spectrophotometry.;TNF-a. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: ELISA.;IL-6. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: ELISA.;IL-8. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: ELISA.;Hs-CRP. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: ELISA.;Omentin. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: ELISA.;BUN. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: Spectrophotometry.;Creatinin. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: Spectrophotometry.;Uric Acid. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: Spectrophotometry.	—

Measure

Time frame

AST. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: Spectrophotometry.;ALT. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: Spectrophotometry.;ALKP. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: Spectrophotometry.;TP. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: Spectrophotometry.;Alb. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: Spectrophotometry.;TNF-a. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: ELISA.;IL-6. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: ELISA.;IL-8. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: ELISA.;Hs-CRP. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: ELISA.;Omentin. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: ELISA.;BUN. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: Spectrophotometry.;Creatinin. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: Spectrophotometry.;Uric Acid. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: Spectrophotometry.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSeyyed Mehdi Mirhashemi

Qazvin University of Medical Sciences

mirhashemism@gmail.com+98 28 3333 6001

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026